American Association for Cancer Research
Browse
00085472can064477-sup-can_6-1-07_kondo.pdf (38.65 kB)

Supplementary Table 1 from Epigenetically Controlled Fibroblast Growth Factor Receptor 2 Signaling Imposes on the RAS/BRAF/Mitogen-Activated Protein Kinase Pathway to Modulate Thyroid Cancer Progression

Download (38.65 kB)
journal contribution
posted on 2023-03-30, 17:25 authored by Tetsuo Kondo, Lei Zheng, Wei Liu, Junichi Kurebayashi, Sylvia L. Asa, Shereen Ezzat
Supplementary Table 1 from Epigenetically Controlled Fibroblast Growth Factor Receptor 2 Signaling Imposes on the RAS/BRAF/Mitogen-Activated Protein Kinase Pathway to Modulate Thyroid Cancer Progression

History

ARTICLE ABSTRACT

Fibroblast growth factor (FGF) signals play fundamental roles in development and tumorigenesis. Thyroid cancer is an example of a tumor with nonoverlapping genetic mutations that up-regulate mitogen-activated protein kinase (MAPK). Here, we show that FGF receptor 1 (FGFR1), which is expressed mainly in neoplastic thyroid cells, propagates MAPK activation and promotes tumor progression. In contrast, FGFR2 is down-regulated in neoplastic thyroid cells through DNA promoter methylation. Reexpression of FGFR2 competes with FGFR1 for the immediate substrate FGFR substrate 2 to impede signaling upstream of the BRAF/MAPK pathway. These data unmask an epigenetically controlled FGFR2 signal that imposes precisely on the intragenically modified BRAF/MAPK pathway to modulate thyroid cancer behavior. [Cancer Res 2007;67(11):5461–70]

Usage metrics

    Cancer Research

    Categories

    Keywords

    cancer

    Licence

    CC BY

    Exports